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Thiazolidinediones provide better renoprotection
than insulin in an obese, hypertensive type II diabetic
rat model
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Hyperinsulinemia has been implicated in the development of
diabetic nephropathy. In the present study we compared the
renoprotective effects of the thiazolidinedione, pioglitazone
(PGZ), to that of insulin in a hypertensive, obese, type II
diabetic rat model. PGZ aggravated obesity and gave less
glycemic control than insulin. However, renoprotection was
markedly better with PZG compared to insulin as shown by
lower proteinuria, improved renal function, and less
histological evidence of diabetic glomerular and
tubulointerstitial lesions. PZG and insulin both reduced renal
accumulation of pentosidine and oxidative stress to a similar
extent. In contrast, PGZ but not insulin suppressed enhanced
transforming growth factor-b (TGF-b) expression. We further
confirmed in cultured rat proximal tubular cells that insulin
enhanced TGF-b mRNA expression and protein production.
Our results identify hyperinsulinemia and the attendant
increase of TGF-b expression as potential therapeutic targets
in diabetes independent of glycemic control. This confirms
prior clinical evidence that PZG provides renoprotection in
obese, diabetic patients with nephropathy.
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Strict glycemic control of diabetic patients with nephropathy
is associated with reduction of microalbuminuria,1–3 a critical
marker for the progression and outcomes not only of renal4–6
but also of cardiovascular disease.7 Recent studies in man
have emphasized that insulin resistance or hyperinsulinemia
plays an additional role in the development of type II diabetic
nephropathy.8–10
Thiazolidinediones (TZDs) are a new class of agents that
lower insulin resistance and thus blood glucose. They have
therefore been included in the standard treatment for
diabetic nephropathy. They reduce fasting insulin levels,11–13
which are correlated with a decrease in urinary albumin
excretion.8–10 Despite a similar glycemic control,12,13 they
lower urinary albumin excretion significantly more than
other types of glucose-lowering agents. As a consequence, the
clinical benefit of insulin treatment alone in obese patients
with type II diabetes with the metabolic syndrome is
questioned.
This study was undertaken to address this clinically
important issue. Do TZD, pioglitazone (PGZ), and its
attendant correction of hyperinsulinemia provide a better
renoprotection than insulin despite similar glucose levels?
The spontaneously hypertensive/NIH-corpulent rat (SHR/
NDmcr-cp), a model of type II diabetes with nephropathy,
was chosen to answer this question. This strain has the same
genetic background as SHR but has an additional genetic
mutation in the leptin receptor gene, which leads to
hyperphagia with an attendant wide range of metabolic
abnormalities similar to those of human type II diabetes
(obesity, hyperglycemia, hyperlipidemia, and hyperinsuline-
mia). Glomerular and tubulointerstitial damage character-
istic of human type II diabetic nephropathy, for example
focal and segmental glomerular sclerosis, mesangial expan-
sion, thickening of basement membrane, inflammatory cell
infiltration, and tubulointerstitial fibrosis, develops in this
model together with evidence of an increased oxidative stress
and the accumulation of advanced glycation end products
(AGEs).14–16
PGZ provided a poorer glycemic control than insulin, whereas
PGZ reduced plasma total cholesterol level more effectively. Both
PGZ and insulin failed to modify hypertension. However,
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only PGZ decreased insulin levels, reduced proteinuria, and
improved renal lesions. This benefit was traced to the
improvement of hyperinsulinemia and an attendant fall in
circulating transforming growth factor (TGF)-b.
RESULTS
Metabolic syndrome
Physical and biological data of experimental animals at the
end of the study (aged 39 weeks) are summarized in Figure 1
and Table 1. Compared to control Wistar-Kyoto (WKY) rats,
SHR/NDmcr-cp rats given vehicle exhibited a wide range of
metabolic abnormalities derived from hyperphagia, that is
obesity, hyperglycemia, hyperinsulinemia, hypercholestero-
lemia, and hypertriglyceridemia. Both insulin and PGZ, given
for 26 weeks, significantly improved hyperglycemia, hyper-
cholesterolemia, and hypertriglyceridemia at the end of the
study. Compared with the other agent, insulin achieved a
better glucose control, whereas PGZ reduced plasma total
cholesterol level more effectively. Obesity was not influenced
by insulin but was aggravated by PGZ.
The severe hyperinsulinemia suggests the presence of
insulin resistance in this model.17 As expected, insulin
sensitizer, PGZ, decreased plasma insulin level significantly.
In contrast, insulin treatment dramatically increased plasma
insulin level due to exogenous addition of human recom-
binant insulin.
Hypertension
SHR/NDmcr-cp rats gradually developed hypertension. At
the end of the study (rat age of 39 weeks), their systolic blood
pressure exceeded that of WKY rats (Figure 1f and Table 1).
Neither insulin nor PGZ lowered blood pressure.
Renal involvements
SHR/NDmcr-cp rats developed progressive diabetic nephro-
pathy with severe proteinuria and histological abnormalities
depicted in Figures 2 and 3. The progressive rise in
proteinuria observed in SHR/NDmcr-cp rats given vehicle
was lowered throughout the study by PGZ (Figure 2a).
At the end of the study (rat age of 39 weeks), proteinuria
reached 101.1716.2 mg day1 in vehicle-treated rats vs
9.970.4 mg day1 in WKY rats (Po0.001) and vs 22.77
2.7 mg day1 in PGZ-treated rats (Po0.001). In insulin-
treated rats, by contrast, urinary total protein excretion
fell only for the initial 8 weeks of treatment, but rose
gradually thereafter to reach eventually the level measured in
vehicle-treated rats (P¼ 0.237).
Creatinine clearance (Figure 2b) fell in SHR/NDmcr-cp
rats on vehicle at the end of the study to 1.8070.17 ml min1
vs 3.0070.09 ml min1 in WKY rats (Po0.001). PGZ signifi-
cantly increased creatinine clearance (2.3170.10 ml min1,
Po0.05 vs SHD/NDmcr-cp on vehicle), whereas insulin treat-
ment did not improve creatinine clearance (1.9270.23 ml min1,
P¼ 0.941).
Representative periodic acid-Schiff- or Masson’s tri-
chrome-stained renal pictures obtained at the end of the
study in each animal group are shown in Figure 3. As
compared to the kidney of WKY rats (Figure 3d and h), focal
and segmental sclerosis (Figure 3a) and tubulointerstitial
fibrosis (Figure 3e) were observed in SHR/NDmcr-cp given
vehicle. Glomerular and tubulointerstitial injury (Table 2) were
markedly ameliorated (Po0.001) in SHR/NDmcr-cp given
PGZ (Figure 3b and f). A similar but milder effect (Po0.01)
was noted in rats given insulin (Figure 3c and g), but it was
significantly lower (Po0.001) than in rats given PGZ.
Molecular and biochemical analyses
To understand the mechanisms underlying the difference in
the renal benefits obtained by PGZ and insulin, we
investigated several factors implicated in the pathology of
diabetic nephropathy, that is advanced glycation, oxidative
stress, and TGF-b expression.
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Figure 1 | Metabolic abnormalities. (a) Body weight, (b) blood
glucose, (c) insulin, (d) total cholesterol, (e) triglycerides, and
(f) systolic blood pressure. SHR/NDmcr-cp rats were given vehicle
(DMþV, closed square), PGZ (DMþ PGZ, open square), were given
insulin (DMþ I, open triangle), and WKY rats on vehicle (WKY, closed
triangle). Drug treatment was initiated at the age of 13 weeks after
birth and lasted for 26 weeks. #Po0.05, ##Po0.01, ###Po0.001, WKY
vs DMþV; *Po0.05, **Po0.01, ***Po0.001, DMþV vs DMþ PGZ or
DMþ I; wPo0.05, wwPo0.01, wwwPo0.001, DMþ PGZ vs DMþ I.
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Advanced glycation
Advanced glycation and its protein modifications, called
AGEs, have been implicated in diabetic renal injury.18–20 The
renal contents of pentosidine were taken as a marker of AGEs
(Figure 4a). At the end of the study, it was markedly higher in
the SHR/NDmcr-cp group on vehicle (Po0.001) than in the
WKY group. Insulin (Po0.05) and PGZ (Po0.01) treat-
ments significantly reduced it to the same extent.
The in vivo AGE-lowering mechanism of PGZ and insulin
differs from that of the other previous AGE inhibitory
compounds. Indeed, unlike PGZ, aminoguanidine, pyridox-
amine, and olmesartan (ARB) inhibit advanced glycation
in vitro. The half-maximal inhibition (IC50) values of pentosi-
dine formation during 1-week incubation of uremic plasma
are 8.27, 5.42, and 1.71 mM, respectively, for aminoguanidine,
pyridoxamine, and olmesartan,21–23 whereas that for PGZ exceeds
20 mM. PGZ and insulin most probably lower local AGE
formation through their effect on the prevailing glucose level.
Oxidative stress
Oxidative stress is another therapeutic target for diabetic
renal injury.24 Real-time PCR analysis of the mRNA
expression of nicotinamide adenine dinucleotide phosphate
oxidase, one of the major sources of cellular reactive oxygen
species, was performed in kidney tissues. The mRNA
expressions of two subunits of nicotinamide adenine
dinucleotide phosphate oxidase, Nox2 (otherwise known as
gp91phox Figure 4b) and p47phox (Figure 4c), were clearly
increased in SHR/NDmcr-cp rats on vehicle compared to
WKY rats. Both insulin and PGZ significantly decreased
mRNA expressions of Nox2 and p47phox.
Renal pentosidine content was significantly (Po0.01)
correlated with Nox2 mRNA expression (Figure 4d), a
finding suggesting that AGE formation is linked not only
to hyperglycemia but also to oxidative stress.18,19
TGF-b expression
TGF-b is a pivotal factor in the development of diabetic renal
injury.25,26 As shown in Figure 5a, TGF-b mRNA expression
in kidney tissues was significantly higher (Po0.01) in SHR/
NDmcr-cp rats on vehicle than in WKY rats. This rise was
markedly suppressed by PGZ (Po0.001) but not by insulin.
The renal expression of insulin receptor mRNA was
significantly lower (Po0.01) in SHR/NDmcr-cp rats on
vehicle than in WKY rats (Figure 5b). PGZ and insulin did
not modify this fall in insulin receptor expression.
We further tested in vitro, in cultured rat proximal tubular
cells (IRPTC), the effect of insulin on TGF-b mRNA. Insulin,
fortified in the culture medium for 48 h, significantly
increased mRNA expression of TGF-b dose-dependently
(Figure 6a) with a parallel increase of TGF-b protein secreted
in the culture soup (Figure 6b), confirming the pleiotropic
effects of insulin.
DISCUSSION
To the best of our knowledge, the renoprotective effectiveness
of TZDs and insulin has not yet been compared in human or
in animal studies, whereas renoprotection of TZDs was
documented in a type II diabetic animal study.27 In this
study, we demonstrate that PGZ protects the diabetic kidney
markedly better than insulin. As pointed out earlier, our rat
SHR/NDmcr-cp model has the metabolic, biological, and
hypertensive characteristics of human type II diabetic
nephropathy.15,16 Strikingly, PGZ but not insulin reduced
proteinuria, preserved renal function, and eventually im-
proved diabetic glomerular and tubular lesions.
Table 1 | Physiological and biochemical data of the experimental rats at the end of the study
WKY DM+V DM+PGZ DM+I
Body weight (g) 50073 672717### 760710*** 690737
HbA1c (%) 3.370.0 5.370.3### 4.170.1*** 3.370.2***,ww
Blood glucose (mg dl1) 12072 16775### 16778 112711***,www
Insulin (ng ml1) 1.670.1 60.1710.5### 5.470.6*** 472.2741.7***,www
Total cholesterol (mg dl1) 12873 186710### 6774*** 13278***,www
Triglyceride (mg dl1) 3972 407744### 223725** 221742**
Systolic blood pressure (mm Hg) 13973 17074### 18076 17876
PGZ, pioglitazone; WKY, Wistar-Kyoto rat.
###Po0.001, WKY vs DM+V; **Po0.01, ***Po0.001, DM+V vs DM+PGZ or DM+I; wwPo0.01, wwwPo0.001, DM+PGZ vs DM+I.
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Figure 2 | Renal functions. (a) Urinary protein excretion and (b)
creatinine clearance. SHR/NDmcr-cp rats were given vehicle (DMþV,
closed square), PGZ (DMþ PGZ, open square), were given insulin
(DMþ I, open triangle), and WKY rats on vehicle (WKY, closed
triangle). PGZ significantly reduced urinary protein excretion
throughout the whole period. By contrast, insulin reduced urinary
total protein excretion only for the initial 8 weeks of treatment.
Urinary protein excretion gradually increased thereafter and
eventually there was no significant difference between SHD/NDmcr-
cp on vehicle and on insulin. ###Po0.001, WKY vs DMþV; *Po0.05,
**Po0.01, ***Po0.001, DMþV vs DMþ PGZ or DMþ I; wPo0.05,
wwPo0.01, wwwPo0.001, DMþ PGZ vs DMþ I.
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Drug treatment was initiated in rats at the age of 13 weeks
and continued till killing at the age of 39 weeks. Neither
insulin nor PGZ corrected obesity and hypertension.
Glycemic control was improved but more so with insulin
than with PGZ. However, only PGZ significantly decreased
insulin levels, whereas insulin treatment aggravated the
hyperinsulinemia.
The mechanisms of PGZ renoprotection remain to be
discussed. Hyperglycemia contributes to renal injury through
an enhanced polyol pathway, advanced glycation leading to
the production of toxic AGEs, protein kinase C activation,
and other processes.28–30 In our model, insulin treatment did
not retard diabetic renal injury despite the correction of
hyperglycemia and hyperlipidemia. PGZ, by contrast, pro-
vided renoprotection despite a suboptimal glucose control
and an increased body weight. Glycemic and body weight
control are thus unlikely contributors to the benefits of PGZ.
The renoprotective effect of PGZ has been attributed by
some researchers to a decreased blood pressure.31,32 In our
study, however, PGZ had no such effect, a finding in
good agreement with previous reports.33,34 Still, in vitro
studies have demonstrated that TZDs interfere with the
renin–angiotensin system,35 so that we cannot exclude a
possible role of a local modulation of the renin–angiotensin
system within the kidney.
PGZ appears to protect the kidney mainly through a
reduction of the elevated insulin levels characteristic of the
SHR/NDmcr-cp rat. Insulin, indeed, increases mesangial cell
proliferation and interstitial matrix accumulation.36–39 In an
in vivo study, insulin infusion in type II diabetic patients
increased renal albumin excretion.40 The reduction of
proteinuria is correlated with the decrease in fasting insulin
levels in diabetic patients given TZDs,8–13 in contrast with the
weak or absent correlation with fasting glucose or HbA1c
levels.11,41
Other intermediates of PGZ’s beneficial effects on diabetic
nephropathy have been ruled out. The role played by
advanced glycation and the formation of toxic AGEs has
been previously emphasized.29,30 Our results rule out the
major contribution played by advanced glycation, because
both PGZ and insulin reduced equally the renal content of
pentosidine, probably through the improved glycemic
control as both agents are devoid of AGE-lowering activity
in vitro.
DM+V DM+PGZ DM+I WKY
DM+V DM+PGZ DM+I WKY
a b c d
e f g h
Figure 3 | Glomerular sclerosis and tubulointerstitial fibrosis. (a–d) Periodic acid-Schiff-stained and (e–h) Masson trichrome-stained renal
tissues. SHR/NDmcr-cp rats on (a and e) vehicle, (b and f) PGZ, or (c and g) insulin, and (d and h) WKY rats on vehicle at the end of the study.
PGZ markedly improved glomerular sclerosis and tubulointerstitial fibrosis, whereas insulin failed to improve diabetic renal lesions. Original
magnifications: (a–d)  400 and (e–h)  200.
Table 2 | Morphologic evaluation of glomerular sclerosis and tubulointerstitial fibrosis at the end of study
WKY DM+V DM+PGZ DM+I
Glomerular sclerosis score 0.1470.02 0.9570.05### 0.3870.02*** 0.7870.02**,www
Tubulointerstitial fibrosis (%) 1.870.2 13.270.7### 3.870.3*** 9.771.0**,www
PGZ, pioglitazone; WKY, Wistar-Kyoto rat.
###Po0.001, WKY vs DM+V; **Po0.01, ***Po0.001, DM+V vs DM+PGZ or DM+I; wwwPo0.001, DM+PGZ vs DM+I.
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Oxidative stress has been incriminated in diabetic
nephropathy. Although a generalized oxidative stress has
been ruled out by the group of Baynes,42 we have provided
evidence that diabetic renal damage is associated with a local
oxidative stress,18,19 a finding confirmed in diabetic vascular
lesions by the group of Heinecke.43 In this study, both PGZ
and insulin interfere to the same degree with the oxidative
stress, assessed by mRNA expressions of two subunits of
nicotinamide adenine dinucleotide phosphate oxidase, Nox2,
and p47phox. It is of note that evidence of local oxidative
stress was correlated with the renal accumulation of AGEs,
independently of prevailing glucose levels. At any rate, in this
study, oxidative stress does not seem to be involved in the
primary benefits of PGZ.
An increased TGF-b level appears to be a pivotal factor in
the development of diabetic glomerulosclerosis and tubu-
lointerstitial fibrosis.25,26 In our study, PGZ, but not insulin
treatment, markedly decreased the elevated TGF-b expression
observed in the SHR/NDmcr-cp rat kidney. The different
effects between PGZ and insulin paralleled a similar
difference in the levels of insulin achieved by both drugs,
but were not explained by the altered levels of insulin
receptors. In an in vitro study of cultured rat proximal
tubular cells, we confirmed that insulin upregulates TGF-b
mRNA and protein. The augmentation of TGF-b protein by
insulin was also reported previously by Morrisey et al.,39
although insulin did not affect TGF-b mRNA in their studies
utilizing another type of cultured tubular cell line, HK-2.
Alternatively, PGZ may directly suppress TGF-b expression in
proximal tubular cells.44
The relationship between TGF-b and diabetic nephro-
pathy is of great interest. We have previously demonstrated in
the same diabetic rat strain that ARBs protect the diabetic
kidney, a finding attributed, at least in part, to specific drug-
related inhibition of advanced glycation and oxidative
stress.14,15 It has been recently demonstrated that ARBs also
depressed TGF-b levels,45,46 raising the possibility that the
ARBs and TZDs renoprotection share a common mediator.
Taking into account the in vitro AGE-lowering potential of
ARBs, it will be of interest to evaluate whether their
combination with PGZ provides an augmented benefit.
A large number of factors contribute to the genesis and
progression of diabetic nephropathy. In this study, we
demonstrate that two glucose-lowering agents, PGZ and
insulin, given to obese, hypertensive type II diabetic rats with
nephropathy have a strikingly different impact on renopro-
tection. Although both share the same influence on obesity,
hypertension, glycemic control, renal accumulation of AGEs,
or oxidative stress, only PGZ protects the diabetic kidney.
The lower insulin levels and their attendant decrease in TGF-
b expression observed with PGZ offer the best explanation
for this difference. The benefits of the correction of the
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metabolic syndrome, and of the reduced advanced glycation
and oxidative stress, achieved by insulin treatment are
mitigated, at least in part, by the activation of TGF-b
production.
Our results, obtained in a rat model, can probably be
extended to humans, as they agree with clinical studies
showing that PGZ offers an enhanced renoprotection in
obese diabetic patients with nephropathy.
In conclusion, our data suggest that hyperinsulinemia
together with a stimulated TGF-b expression significantly
contributes to the genesis and deterioration of diabetic
nephropathy. This role appears independent of other causal
factors such as glycemic control, hypertension, obesity,
advanced glycation, and oxidative stress. Hyperinsulinemia
becomes thus an additional therapeutic target for clinicians
eager to prevent the disastrous consequences of diabetes.
MATERIALS AND METHODS
Animals
Animal experiments were performed in accordance with the
guidelines of the Committee on Ethical Animal Care and Use of
Tokai University. Male SHR/NDmcr-cp and WKY rats were
purchased from SLC (Shizuoka, Japan). All rats were housed in
individual cages in a temperature- and light-controlled environment
in an accredited animal care. SHR/NDmcr-cp rats, aged 13 weeks,
were randomly divided into three groups. Group 1 (n¼ 10) received
vehicle orally (DMþV), group 2 (n¼ 10) received PGZ orally
(3 mg kg1 per day) (DMþ PGZ), and group 3 (n¼ 9) received
insulin subcutaneously (30 U kg1, twice a day) (DMþ I). WKY rats
(n¼ 10) served as a control group (WKY). Drug treatment lasted for
26 weeks.
Blood pressure, urine collection, and blood sampling
Systolic blood pressure was determined in conscious rats by the tail-
cuff method at the beginning of the study, at 2 weeks, at 4 weeks,
and every 4 weeks subsequently until euthanasia. Rats were housed
in metabolic cages for overnight collection of urine, and blood
samples were obtained at the beginning of the study, at 2 weeks, at 4
weeks, and every 4 weeks subsequently.
Blood and urine biochemistry
Glucose, total cholesterol, triglycerides, and creatinine concentra-
tions in plasma, and protein and creatinine concentrations in urine
were determined with an automatic analyzer (Hitachi Automatic
Clinical Analyzer 7170, Hitachi Science Systems, Ibaraki, Japan).
Plasma insulin was measured with a commercially available kit
(Morinaga Biochemistry Lab, Tokyo, Japan). HbA1c was measured
using DCA2000 (Bayer Diagnostics, Pittsburgh, PA, USA) at the end
of the study.
Semiquantitative evaluation of glomerulosclerosis
Kidney sections (4-mm thickness) fixed in methyl-Carnoy’s solution
were stained with periodic acid-Schiff and examined by light
microscopy in a blinded manner. Glomerular sclerosis was
semiquantitatively evaluated by a previously described method.15,16
Briefly, 50 glomeruli were selected randomly in each animal for
morphometric analysis. The severity of glomerular sclerosis was
graded according to the damaged glomerular area expressed as a
percentage of total area: 0, no lesions; 1þ , 1–25%; 2þ , 25–50%;
3þ , 50–75%; and 4þ , 75–100%. An overall glomerular sclerosis
score per animal was obtained by multiplying each severity score
(0–4þ ) with the percentage of glomeruli displaying the same degree
of injury and summing these scores.
Semiquantitative evaluation of tubulointerstitial fibrosis
Kidney tissues (4-mm thickness) were fixed in 10% neutral buffered
formaldehyde and stained with Masson’s trichrome for morpho-
metric analysis. Digital images of trichrome-stained renal cortex
areas were obtained at  200 by an observer blind to the identity of
the sections. Interstitial trichrome-positive areas were counted for
evaluation of interstitial fibrosis using the capacity of software
Image-Pro Plus (Planetron Inc., Tokyo, Japan) to select areas of
matching color intensity. Trichrome stain-positive areas on
glomeruli, Bowman’s capsules, or vessels were excluded. Ten
randomly chosen areas were measured in each rat. All rats were
analyzed per group.
Renal pentosidine content
Kidney tissue (100 mg) was minced, rinsed with 10% trichloroacetic
acid, dried under vacuum, and acid hydrolyzed in 500 ml of 6 N HCl
for 16 h at 1101C under nitrogen. Pentosidine was analyzed on a
reverse-phase high-pressure liquid chromatography as described
previously.47,48 In brief, a 20-ml aliquot of the acid hydrolysate
diluted by phosphate-buffered saline was injected into a high-
pressure liquid chromatography system and separated on a C18
reverse-phase column (Waters, Tokyo, Japan). The effluent was
monitored with a fluorescence detector (RF-10A; Shimadzu,
Kyoto, Japan) at an excitation–emission wavelength of 335/385 nm.
Synthetic pentosidine was used as a standard.
Gene expression analysis
Real-time PCR was performed to evaluate the mRNA expression of
insulin receptor, TGF-b, and nicotinamide adenine dinucleotide
phosphate oxidase subunits, Nox2 and p47phox. Total RNA was
extracted from renal tissues of experimental rats and from cultured
rat proximal tubular cells using the RNeasy mini kit (QIAGEN
GmbH, Hilden, Germany). Real-time PCR was performed with the
One Step RT-PCR Kit (Takara, Bio Inc., Shiga, Japan), SYBR Green I
reagent (Cambrex Bio Science, Rockland, ME, USA), and iCycler
PCR system (Bio-Rad Laboratories, Hercules, CA, USA) according
to the manufacturer’s instructions. Primer sequences are listed as
follows: insulin receptor (forward 50-GATGTCACCCGAGTCCCT
GAA-30, reverse 50-GGATCCAGATAGCCTCCATCCA-30), TGF-b
(forward 50-TGCGCCTGCAGAGATTCAAG-30, reverse 50-AGGTAA
CGCCAGGAATTGTTGCTA-30), Nox2 (forward 50-CGGGACTTCG
GACCCATATTC-30, reverse 50-ATTCCTGTGATGCCAGCCAAC-30),
p47phox (forward 50-CCACGGGTATTGCTAGGATGAGA-30, reverse
50-AGACTAAGGCAGCGGGTAATCAGA-30), and glyceralde-
hyde-3-phosphate dehydrogenase (forward 50-GACAACTTTGGC
ATCGTGGA-30, reverse 50-ATGCAGGGATGATGTTCTGG-30). Glycer-
aldehyde-3-phosphate dehydrogenase mRNA expression was used
for normalization.
Insulin stimulation assay in vitro
IRPTC is a cell line originating from proximal tubular cells of male
Wistar rats, immortalized by transformation with origin-defective
SV40 DNA.49 IRPTC was cultured in Dulbecco’s modified Eagle’s
medium, supplemented with 10% fetal bovine serum. At 80%
confluence, the medium was changed to serum-free Dulbecco’s
modified Eagle’s medium and cells were stimulated with 0, 5, 50, or
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500 ng ml1 insulin for 48 h (n¼ 9). After treatment, the super-
natant was collected for measuring TGF-b contents, and RNA was
isolated from cells with the RNeasy mini kit for real-time PCR
analysis. TGF-b in the supernatant was measured with a commer-
cially available kit (R&D Systems Inc., Minneapolis, MN, USA).
Statistical analysis
All data are reported as the mean7s.e. Statistical analysis was
performed using a one-way analysis of variance followed by Tukey’s
post hoc test with SPSS for Windows version 15.0 (SPSS, Chicago, IL,
USA). Common logarithm of serum insulin was used for
comparison, due to different order of magnitude. The Spearman’s
correlation test was used to correlate pentosidine with Nox2
expression. Po0.05 was considered significant.
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